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Abstract: The pathogenesis of cyclophosphamide-induced hemorrhagic cystitis (CP-HC) is complex, involving the im-
pact of many systemically and locally released agents on autonomic nervous system (ANS) activity, that affects bladder 
functioning.
The purpose of our study was to provide an indirect evaluation of ANS functional status in experimental CP-HC model, 
involving prostaglandin synthesis block resulting from administration of cyclooxygenase inhibitors.
The ANS activity was estimated through the spectral analysis of heart rate variability (HRV) in CP-HC rats divided into 
three study groups: 1-control, 2-treated with meloxicam (MLX) that preferentially blocks COX-2, and 3-treated with 
piroxicam (PRX) that inhibits COX1 and 2 activity.
In animals treated either with MLX or PRX, the percent distribution of the spectrum in relation to components of very 
low (VLF) and low (LF) frequency was not different from the control group. PRX-treated group displayed nearly two 
times lower percent share of the high frequency (HF) component compared to the control. Moreover, an increase of the 
normalized LF (nLF) value with simultaneous reduction of the normalized HF (nHF) value were noted in PRX-treated 
rat with no change of these parameters for MLX-treated rats.
The HRV analysis in CP-HC rats receiving PRX, indicated a functional reorganization manifested by reduced parasym-
pathetic activity and increased sympathetic tonus. A partial prostaglandin synthesis block caused by COX-2 inhibitor 
(meloxicam) caused no significant changes of evaluated HRV parameters compared to the control. Assessing functional 
changes of the ANS caused by prostaglandin synthesis block it should be stated that prostaglandins synthesized by the 
constitutive COX-1 isoform seem to maintain the parasympathetic activity, which may be associated with the cholinergic 
anti-inflammatory pathway and resolution of inflammation in course of cyclophosphamide-induced cystitis. 
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Introduction
Urinary bladder overactivity symptoms are observed both in functional and organic morbid-
ities of the bladder. One of clinical circumstances associated with development of symptoms 
of secondary overactive bladder syndrome (OAB) is hemorrhagic cystitis caused by therapy 
with drugs belonging to the group of oxazaphosphorins, especially with cyclophosphamide 
(CP). The drug is still commonly used in therapy of lymphoproliferative conditions, Hod-
gkin disease and neoplastic diseases (e.g. small-cellular lung cancer or breast cancer), and 
in therapy of other diseases, including nephrotic syndrome or visceral lupus [1]. However, 
the use of cyclophosphamide is associated with risk of numerous and multi-systemic ad-
verse effects, including the above mentioned hemorrhagic cystitis with bladder overactivity 
[2]. Pathogenesis of cyclophosphamide-induced hemorrhagic cystitis (CP-HC) is a com-
plex one, associated with systemic biotransformation of oxazaphosphorins and endoves-
ical release of a toxic metabolite — acrolein — secondary initiating release of numerous 
preformed and de novo synthesized pro-inflammatory mediators, and finally inducing 
cellular damage. A detailed description of CP-HC pathogenesis is presented in one of our 
reviews [3].
CP-HC prevention and therapy is based on parallel administration of cytoprotective 
agents, mainly mesna (a donor of sulfhydryl groups that react with the double bond in 
acrolein, transforming that oxazaphosphorine metabolite into a less toxic product) [4]. 
Other, currently studied cytoprotective agents potentially effective in CP-HC therapy in-
volve phytopharmacological compounds (belonging to groups of flavonoids, vitanoloids, 
steroidal saponins, vegetable alkaloids and organic sulphur compounds) [3] and prosta-
glandins analogues [5]. It is generally known that prostaglandins are synthesized locally 
in the stomach and exert their cytoprotective action towards the gastric mucosal barrier, 
as well as mucous barrier and mucosal perfusion [6]. Prostaglandins are also released by 
vesical urothelium and demonstrate similar cytoprotective properties [7]. At the same 
time, there are reports from studies on pathogenesis of idiopathic OAB, suggesting that 
prostaglandins increase the contractility activity of the detrusor. Therefore, those com-
pounds may be perceived as one of paracrine mediators, that may contribute to bladder 
overactivity [8].
Considering the above mentioned premises associated with a potential, alleviating ef-
fect of prostaglandins administered in CP-HC, it is worth explanation if those compound 
are also able to modulate the activity of the autonomic nervous system (ANS), and, if those 
potential changes in autonomic regulation could contribute to their protective properties 
in course of CP-HC. Hence, our purpose was to indirectly assess the autonomic activity 
in experimental CP-HC by spectral heart rate variability (HRV) method, utilizing effects 
resulting from prostaglandin synthesis inhibition by non-steroid anti-inflammatory drugs 
(NSAIDs). Moreover, using a non-selective inhibitor of COX-1 and COX-2, or a preferential 
COX-2 inhibitor, we were trying to determine if the potential effect on ANS activity was 
demonstrated by constitutive or inflammatory-induced prostaglandins. 
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Materials and methods
Ethical aspects of the experiment
The medical experiment described in this paper was approved by the 1st Local Bioethical 
Committee for Animal Experiments in Krakow (approval’s No 124/2013).
Study animals
The experiment was conducted on thirty 8-weeks old female Wistar rats obtained from the 
central animal house of the Pharmacy Faculty at the UJCM in Krakow. At arrival to the 
animal house of the Chair of Pathophysiology UJCM rats were placed in 5 cages, with un-
limited access to water and standard laboratory feed (Labofeed, Kcynia). The experiment 
was conducted following a 10-day acclimatization period. After that time animals were 
randomly assigned to study groups.
Study groups and general outline of the experiment
The study was carried out in animals with experimentally induced CP-HC, divided into three 
groups of 10 participants each: 1 — control (CP-HC animals without additional treatment), 
2 — CP-HC animals receiving the preferential cyclooxygenase 2 inhibitor — meloxicam and 
3 — animals receiving the non-specific cyclooxygenase inhibitor — piroxicam. Baseline and 
end-of-experiment body weight was determined in each study group. Water and feed con-
sumption during the experiment were not monitored, and animals had an unlimited access 
to both. All study animals had cyclophosphamide-induced cystitis induced for 7 days, and 
during this period groups 2 and 3 received additionally cyclooxygenase inhibitors: MLX in the 
group 2, and PRX in the group 3, while control animals were sham treated (0.9% saline solu-
tion). On the day 8 of the experiment all rats had heart rate variability (HRV) recordings, and 
then, following administration of a lethal dose of pentobarbital — cystectomy was performed 
in order to determine bladder wet weight (BWW) and for further histopathological evalua-
tion. Characteristics of study animals and BWW results are presented in the Table 1, below.
Table 1. Characteristics of study groups.
Rats’ body weight
Statistic Bladder wetweight [mg] Statistic
Bladder wet 
weight/body 
weight ratio [%]
Statistic
Starting [g] Final [g]
CP-HC
Group 1
210.3 ± 12,0
178.7 ± 16.1 – 170 ± 60 – 0.095 ± 0.04 –
CP-HC + MLX
Group 2 187.3 ± 10.7 NS 150 ± 20 NS 0.080 ± 0.01 NS
CP-HC + PRX
Group 3 156.3 ± 19.6 NS 130 ± 40 p = 0.05 0.083 ± 0.02 NS
NS — non significant
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Experimental model of hemorrhagic cystitis
All rats were intraperitoneally administered cyclophosphamide (CP) at the dose of 75 mg/kg 
b.w. (at the first, third, fifth and seventh day of the experiment) in order to induce 
a chronic cyclophosphamide-induced cystitis. According to numerous literature reports, CP 
administered four times in dosing scheme described above, results in development of CP-HC 
[9, 10]. We have also confirmed the fact in our previous studies using that method and per-
forming pathomorphological evaluation of bladders, and verifying with urodynamic records 
of bladder overactivity [11]. Cyclophosphamide was obtained in the crystalline form from 
Sigma Aldrich (cyclophospamide monohydrate) and was prepared in form of an aqueous 
solution ex temporae, before administration of subsequent doses. 
Therapy with cyclooxygenase inhibitors
MLX and PRX were administered respectively to animals in groups 2 and 3, in an hour fol-
lowing the administration of CP. Commercially available formulas were used (meloxicam — 
MOVALIS, Boehringer Ingelheim, ampoules 15 mg/1.5 ml; piroxicam — FELDENE, Pfizer, 
ampoules 20mg/ml). Rats in the control group received i.p. injections with normal saline 
in the mean volume corresponding to PRX/MLX doses. Following an appropriate dilution 
with water for injection, a defined dose of study agents was intraperitoneally administered, 
similarly to CP. We have used the dose of 10 mg/kg b.w. of piroxicam, considering experience 
gained by other researchers who used PRX at the dose of 10 mg/kg b.w. [12] or 5 mg/rat 
with body weight of approx 400 g [13]. Selection of meloxicam dose of 5 mg/kg b.w. was 
based on reports published by Laird et al. study [14] who used the compound in rats at 
doses ranging between 0.1 and 4 mg/kg b.w., everyday for 5 days, and reports published 
by Bourque et al. [15], who administered MLX at the dose of 1–2 mg/kg b.w. every day for 
3 days, subcutaneously. On that basis we concluded that our meloxicam administration 
regimen involving i.p. injection at the dose of 5 mg/kg b.w., every other day, will be finally 
a similar dosing scheme. 
Animals lost during the study
In the control group (group 1) two animals died before administration of the last, fourth 
CP dose. Therefore, finally the group consisted of 8 animals. Other rats demonstrated nor-
mal activity, but their condition deteriorated progressively under the unfavorable, systemic 
effect of CP. The deterioration was manifested by body weight loss measured in relation to 
the baseline (Table 1).
All animals with CP-HC treated with MLX (group 2) survived until the end of the ex-
periment, and in the group 3 (CP-HC+PRX) three animals died. Therefore, 7 animals were 
studied finally in that group. In both groups 2 and 3, similarly to the control group, body 
weight reduction was observed, being a result of unfavorable effect of CP. A relatively poor-
er condition of rats in the group 3 (manifested by the number of dead animals) could be 
also associated with potential adverse effects of PRX to alimentary tract mucosa (Table 1).
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ANS function estimation by HRV recording
On the day 8 of the experiment, an indirect assessment of the autonomic nervous system 
activity using the heart rate variability, based on electrocardiographic records, was performed 
in all study groups. ECG was registered in rats under general urethane anesthesia (1200 mg/kg 
b.w.; i.p.) at rest, for 20 minutes. Before the ECG registration rats’ abdomens were care-
fully shaved in order to achieve epidermal abrasion, and a standard ECG gel was applied. 
The record was performed using pediatric Ag/AgCl electrodes (EG-S30 PSG Sorimex) 
placed according to the classic configuration, to achieve one ECG lead. During the 
registration rats were placed under a heating lamp to protect them from reduced body 
temperature.
After the registration, the obtained ECG signal was evaluated visually in order to remove 
any extra-sinus stimulations and the record was analyzed for heart rate variability. The start-
ing point in the HRV analysis is the assessment of duration of neighboring „normal-normal” 
(N-N) intervals, that undergo constant, autonomically-controlled fluctuations [16]. Currently, 
HRV is considered to be the best, non-invasive, indirect method for the autonomic functional 
status estimation, allowing to carry out two types of analysis: time (adopted especially for 
long-term ECG recordings) and spectral ones [16, 17]. We decided to base our reasoning on 
spectral (frequency) analysis that results from subjecting of the N-N intervals variability to 
fast-Fourier transformation or autoregression methods. In this procedure, finally powers of 
components of the, so called, HRV spectrum are estimated, that is distribution of RR intervals 
variability changes in relation to cyclic, ANS-modulated stimulating activity of the sinus node 
associated with three principal rhythms: very low frequency (VLF), low frequency (LF), and 
high frequency (HF) [16, 17]. For spectral HRV analysis we adopted the following ranges 
for individual HRV spectral components: 0.18<VLF<0.28<LF<0.78<HF<3. The frequency 
ranges adopted by us were similar to those used by Aubert et al. [18] (0.19<LF<0.74<HF<2.5) 
and Goncalves et al. [19] (0.10<LF<1.0<HF<3.0) Moreover, we assessed the percent share 
of power of individual spectral components (VLF [%], LF [%], HF [%]) in relation to the 
total power of the spectrum, and LF/HF ratio, and values of standardized nLF and nHF 
parameters.
Collection of bladders and their histopathological assessment
Following HRV recording animals were sacrificed with a lethal dose of pentobarbital (Mor-
bital, Puławy, Poland; 100mg/kg b.w.) for weight and histopathological analysis of their 
bladders. The bladder was collected following a previous separation from the surrounding 
fatty tissue and voiding. According to the literature data, measurement of the bladder wet 
weight (BWW) may be treated as an indirect evidence of the bladder reconstruction induced 
by inflammation [20, 21]. Directly after collection, bladders were weighed on an analytic 
scale and then placed in 4% formalin solution with PBS for further histopathological eval-
uation. The detailed description of the histopathological procedure was placed in one of 
our previous paper [22].
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Statistical analysis of results
The statistical analysis was performed using the statistical suite R.3.0.2. (R Foundation for 
Statistical Computing, Vienna, Austria).
First, existence of statistically significant differences between three study groups was 
verified with the variance test analysis (ANOVA). Then, if statistical significance was demon-
strated for an individual analyzed parameter (p <0.05 in ANOVA), differences between groups 
1 and 2 (control CP-HC vs. CP-HC+MLX), and 1 and 3 (control CP-HC vs. CP-HC+PRX) 
were analyzed with the t-Student test. Both tests (ANOVA and t-Student) were done on 
logarithms of obtained HRV results. The procedure was aimed at assurance of higher con-
formity of those parameters with the normal distribution. 
Results
Bladder Wet Weight (BWW) and histopathological evaluation or urinary bladders
The BWW measurement indicated that the parameter reached its highest value in control 
animals, and the lowest in piroxicam-treated ones and this difference was of a statistical sig-
nificance. However, referring the measured BWW valued to the final body weight of animals 
and expressing that association as a percent index, similar results were obtained in all study 
groups, and no statistically significant differences were found (Table 1).
The histopathological analysis revealed non-specific vesicular inflammatory changes in 
all study groups, with signs of congestion, edema, together with presence of lymphocytes 
in mucosal lamina propria (features of papillosis urothelialis focalis). 
HRV spectral analysis
The spectral analysis of HRV records of animals treated with MLX (group 2) demonstrated 
that percent distribution of basic, non-standardized spectral components in those animals 
was nearly identical as in the control group, without any statistically significant differences. 
Similarly, values of normalized nLF and nHF parameters found for the group 2 were not 
statistically significantly different from those in the control group.
In the group 3 (CP-HC+PRX), similarly to the group 2, the percent distribution of the 
spectrum in relation to components VLF and LF was not statistically significantly differ-
ent from the control group, but — contrary to the group 2 — the percent share of the HF 
component was nearly two times lower compared to the control, and the difference was 
statistically significant. Moreover, statistically significant increase of the nLF value with si-
multaneous reduction of the nHF value were noted in the group 3 rats (treated with PRX) 
compared to the control.
Results of basic spectral parameters and their percent distribution in relation to the total 
HRV spectrum power, along with the statistical analysis are presented in the Table 2, below, 
and Figures 1 and 2 show changes of normalized nLF and nHF parameters.
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Table 2. Results of the HRV spectral analysis.
Parameter CP-HCGroup 1
CP-HC+MLX
Group 2
CP-HC+PRX
Group 3
Statistic
Groups 1–2 Groups 1–3
VLF [%]   70.09 ± 12.63 69.02 ± 27.26 77.16 ± 7.99 NS NS
LF [%] 11.41 ± 4.19     10.83 ± 7.54 12.86 ± 4.52 NS NS
HF [%] 18.51 ± 9.87 20.15 ± 25.62   9.98 ± 4.16 NS p = 0.05
LF/HF   0.82 ± 0.55 0.97 ± 0.65   1.14 ± 0.39 NS NS
Fig. 1. Changes of the normalized nLF parameter value in study groups.
Fig. 2. Changes of the normalized nHF parameter value in study groups.
For both figures: A box height stands for the mean value of a logarithm of a parameter in the particular group, and whiskers 
present the 95% confidence interval for the logarithm. 
Both scales: raw and logarithm, were marked to facilitate the interpretation. 
A result of the statistical analysis was marked in relation to the control group (p value or labelled as NS — non significant).
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Discussion
Considering the unquestioned endocrine activity of the urothelium and its role in bladder 
function control, it seems that prostaglandins are a necessary element of homeostasis of the 
organ [8, 23]. They are synthesized locally in the urinary bladder, both in basic (synthesis 
with constitutive COX-1) and pathological (with COX-2 induced by, among other, inflam-
mation) conditions. COX-1 expression is found in the urothelium, whereas both COX-1 and 
COX-2 are expressed in the muscular layer [24]. There are some species-specific differences 
in the prevailing type of prostaglandins released locally in the bladder. However, it may be 
generally stated that the following prostaglandins are present in the bladder: PGE2, PGF2α, 
PGD2 and PGI2 [8].
It is generally accepted that those compounds are principal pro-inflammatory mediators, 
co-responsible for development of all classic symptoms of an acute inflammation (local red-
dening, warming, edema, pain as well as systemic reaction — fever). However, on the other 
hand, there is also an opinion that COX-2 pathway-dependent prostaglandins are also en-
gaged in mechanisms associated with resolution of an inflammation. It is possible that those 
compounds demonstrate their anti-inflammatory effect exerting a beneficial influence on 
urothelium and muscular coat through several mechanisms. Generally speaking, in presence 
of prostaglandins cellular membranes become strengthened and tightened. That results in 
disappearance of edematous changes. Part of prostaglandins stimulate platelet aggregation 
and local vasoconstriction, leading to reduced hematuria. Moreover, PGE2 demonstrates 
cytoprotective properties (similar to those in the stomach), thus protecting from intensifi-
cation of urothelium damage [7, 8].
Those reports undermine the basic dichotomy of the above mentioned division into 
constitutive, homeostatic prostaglandins synthesized with COX-1, and COX-2-induced, 
pro-inflammatory prostaglandins. Those observations also question the paradigm of using 
selective COX-2 inhibitors as a modern anti-inflammatory therapy, for many years perceived 
as safer compared to classic non-selective NSAIDs [25]. 
Pleiotropic properties of prostaglandins involve also their paracrine modulation of 
the autonomic system. Therefore, our aim was to determine the functional status of the 
autonomic nervous system in the experimental CP-HC model, with blocked synthesis of 
prostaglandins. Spectral HRV analysis performed in the group of rats with CP-HC treated 
with MLX demonstrated no statistically significant differences, contrary to the group treat-
ed with PRX. In that group we have demonstrated a functional rearrangement of the ANS, 
with marked percent reduction of the HF component. Those changes were accompanied by 
reduced nHF and increased nLF values. According to the commonly accepted interpretation 
criteria, both the non-standardized HF component, and the standardized nHF parameter 
reflect tension of the parasympathetic part of the ANS, while nLF is an exponent of the 
sympathetic activity [16, 17]. Therefore, our results indicate that administration of piroxicam 
(but not meloxicam) is associated with reduced parasympathetic activity. That conclusion 
may be also supported by the tendency of changes observed within the VLF component of 
the HRV spectrum. Underlying mechanisms of that component remain unclear, and that is 
why its interpretative significance is not as unequivocal, as it is in case of the HF component. 
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However, majority of researchers tend to accept the hypothesis that the VLF component 
is also a marker of sympathetic stimulation associated with activation of the RAA system, 
thermoregulation and activity of chemoreceptors [16, 26]. Whereas the percent increase of 
the VLF component observed by us in the group 3 was not statistically significant compared 
to the control group, combined with simultaneous nLF value increase the trend may reflect 
a parallel intensification of the sympathetic activity following the administration of PRX. 
According to the classification presented in 2008 [27], piroxicam used by us is an com-
pound belonging to the agents blocking both COX isoforms, and meloxicam belongs to the 
preferential COX-s inhibitors. According to other broad reviews, meloxicam is classified 
even as a selective COX-2 inhibitor [28], with consensus among researchers in relation to 
non-selectivity of piroxicam towards COX1 and 2 block [29]. Hence, taking into consider-
ation our results, it should be concluded that prostaglandins synthesized by COX-1 and not 
by COX-2, demonstrate the ability to modulate the autonomic activity. 
The effect of revealed changes in the autonomic activity on the inflammatory condition 
remains a separate question. If inhibition of prostaglandins synthesized by COX-1 results in 
relative increased sympathetic and reduced parasympathetic activity, it should be expected 
that, conversely, prostaglandins themselves intensify the parasympathetic and reduce the 
sympathetic activity. The arguments discussed above is partly consistent with results of our 
another experiment. Recently, we have examined the impact of PGE and PGF2α prosta-
glandin analogues on ANS activity, also estimated with HRV method, in the same experi-
mental CP-HC model [22]. We revealed that animals treated with those compounds were 
characterized by an increase of HRV total power spectrum. Moreover, CP-HC rats treated 
with PGF2α analogue demonstrated an increase of HF power. According to the HRV inter-
pretative guidelines it may suggest a parasympathetic activity predominance in this group of 
animals (on the other hand, however, we did not manage to get a similar conclusion when 
considering the results of standardized nLF and nHF components of HRV spectrum) [22]. 
Such changes in autonomic regulation mat reflect cholinergic mechanisms associated with 
inhibition of activity of inflammatory cells and release of various cytokines — the process is 
referred to as cholinergic anti-inflammatory pathway. It was demonstrated that acetylcholine 
released from parasympathetic fibers acts on nicotine receptors of immunocompetent cells 
(particularly macrophages), leading to reduction of their activity and resolution of inflamma-
tion [30]. Thus, maintenance of the parasympathetic activity by constitutive prostaglandins 
may contribute to alleviation of inflammation through the mechanism of the cholinergic 
anti-inflammatory pathway. That would be consistent with reports regarding a potential ap-
plication of prostaglandins as compounds mitigating urotoxicity of cyclophosphamide [5]. 
Moreover, it should be also stated that demonstration of the favoring effect of prostaglan-
dins on the parasympathetic part would constitute also another evidence of the role of those 
compounds in pathogenesis of idiopathic bladder overactivity (idiopathic OAB syndrome), 
because detrusor contractility increases with cholinergic stimulation of muscarinic receptors 
[7, 8]. Moreover, that would also justify the use of cyclooxygenase inhibitors (NSAIDs) in 
pharmacotherapy of idiopathic OAB syndrome.
We are aware of limitations of our study: autonomic activity assessment was based 
solely on indirect HRV method, without support from biochemical analysis. Besides, our 
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reasoning regarding the modulatory effect of COX1/COX 2 prostaglandins on ANS is indi-
rect and based on HRV records obtained in conditions of inhibition of their synthesis. Also, 
we administrated cyclooxygenase inhibitors (as well as prostaglandin analogues, studied 
in our previously published paper [22]) systemically (i.p.), not intravesically. However, we 
wanted to maintain the same route of administration as in the case of CP and to assess the 
modulatory effects of several PRX/MLX doses of the ANS function in “chronic” conditions 
(our goal was not to study single NSAIDs dose administered intravesically in restrained 
animals).
Moreover, in the histopathological evaluation of bladders, no significant alleviation of 
inflammation or differences in BWW were observed despite the therapy with PRX/MLX. 
That seemingly contradicts the final conclusions. In our opinion, the fact may be a result of 
too short duration of the therapy and resignation from everyday dosing of PRX/MLX, suf-
ficient for induction of the modulating effect on the ANS, but insufficient for the expected, 
anti-inflammatory tissue rearrangement.
Summing up, results of our HRV analysis in the experimental model of cyclophospha-
mide-induced hemorrhagic cystitis indicate a functional rearrangement of the ANS occurring 
following the block of prostaglandin synthesis with a non-selective cyclooxygenase inhib-
itor — piroxicam. The rearrangement was expressed by reduced parasympathetic activity 
and increased sympathetic tension. A partial block of prostaglandin production caused 
by a COX-2 inhibitor — meloxicam brought no significant changes in the ANS function. 
Therefore, assessing the ANS functional changes caused by prostaglandin synthesis block, it 
should be stated that COX-1-mediated prostaglandins maintain the parasympathetic activity 
in experimental cyclophosphamide-induced hemorrhagic cystitis. A cholinergic stimulation 
may be expressed by activation of the cholinergic anti-inflammatory pathway, and in that 
mechanism constitutive prostaglandins may be co-responsible for resolution of inflammation 
in cyclophosphamide-induced cystitis. 
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The list of abbreviations used in the text (in alphabetical order)
ANS — Autonomic Nervous System
BWW — Bladder Wet Weight
COX — Cyclooxygenase
CP — Cyclophosphamide
CP-HC — Cyclophosphamide induced haemorrhagic cystitis
HF — High Frequency component in HRV spectrum
HRV — Heart Rate Variability
LF — Low Frequency component in HRV spectrum
MLX — Meloxicam
nHF — normalized High Frequency component
nLF — normalized Low Frequency component
N-N — Normal-Normal interval (in ECG recording)
NSAIDs — Non Steroidal Antiinflammatory Drugs
OAB — Overactive Bladder
PRX — Piroxicam
VLF — Very Low Frequency component in HRV spectrum 
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